Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy最新文献

{"title":"Extracorporeal Photopheresis as an Immunomodulatory Bridge in Kidney Transplant Recipients With Infections and Concomitant Donor-Specific Antibodies: A Case Series.","authors":"Iacopo Gianassi, Fiammetta Fossi, Leonardo Caroti, Lorenzo Di Maria, Aida Larti, Giulia Antognoli, Renata Angela Di Pietro, Roberta Cutruzzulà, Giuseppe Cestone, Federica Allegretta, Marco Allinovi, Lino Calogero Cirami","doi":"10.1002/1744-9987.70231","DOIUrl":"https://doi.org/10.1002/1744-9987.70231","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney transplant recipients with severe infections often require immunosuppression minimization, increasing the risk of donor-specific antibody (DSA) persistence and antibody-mediated injury. Extracorporeal photopheresis (ECP) may provide immunomodulation while limiting alloimmune activation.</p><p><strong>Methods: </strong>We retrospectively analyzed four kidney transplant recipients with severe infectious complications and concomitant DSAs who required immunosuppression reduction. Clinical scenarios included BK viremia, BK virus nephropathy, Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, and recurrent urinary tract infections. ECP was administered for 12 months as adjunctive therapy.</p><p><strong>Results: </strong>Following ECP initiation, infectious complications improved or resolved in all patients, with reduction of viral replication when present. DSA levels decreased markedly in all cases. Kidney graft function remained stable throughout follow-up, and no episodes of acute rejection were observed.</p><p><strong>Conclusion: </strong>ECP may represent a safe and effective immunomodulatory bridge during immunosuppression minimization in kidney transplant recipients with infections and concomitant DSAs.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manual Versus Automated Biofeedback-Guided Strategies for Isonatremic Hemodialysis: A Real-World Comparative Study.","authors":"A Alayoud, M Azizi, A Sobhi, A Lbid","doi":"10.1002/1744-9987.70229","DOIUrl":"10.1002/1744-9987.70229","url":null,"abstract":"<p><strong>Background: </strong>Achieving neutral sodium balance during hemodialysis is essential to reduce sodium loading while preserving intradialytic hemodynamic stability. Automated biofeedback systems dynamically adjust dialysate sodium concentration using conductivity measurements, but their performance has rarely been compared with a manual individualized isonatremic sodium prescription in routine clinical practice. We compared these two individualized sodium management strategies.</p><p><strong>Methods: </strong>This retrospective, single-center, real-world observational study included 49 adults undergoing maintenance online post-dilution hemodiafiltration between 2022 and 2024. A total of 14 653 dialysis sessions were analyzed, including 8164 sessions using automated biofeedback-guided sodium control targeting a plasma sodium change (ΔNa = 0 mmol/L) and 6489 sessions using a manual individualized isonatremic sodium prescription. Mixed-effects models were used to account for repeated sessions within patients.</p><p><strong>Results: </strong>Automated biofeedback maintained diffusive sodium transfer closer to neutrality than the manual approach (-0.02 ± 2.2 vs. -0.90 ± 2.7 g; adjusted β = 0.37, 95% CI: 0.11-0.62; p = 0.005), while total sodium removal was comparable between strategies. The machine-estimated change in plasma sodium was slightly greater with automated biofeedback (-1.6 ± 1.5 vs. -1.3 ± 1.8 mmol/L; adjusted β = -0.53; p = 0.03). Automated biofeedback was also associated with modestly lower interdialytic weight gain (2.12 ± 1.6 vs. 2.30 ± 1.9 kg; adjusted β = -0.11; p < 0.001) and pre-dialysis systolic blood pressure (140 ± 21 vs. 143.6 ± 22 mmHg; adjusted β = -3.57; p < 0.001). Poor intradialytic tolerance (20.3% vs. 24.9%; OR = 0.76, 95% CI: 0.712-0.816; p < 0.001) and symptomatic intradialytic hypotension (12.9% vs. 14.8%; OR = 0.86, 95% CI: 0.799-0.919; p < 0.001) were also modestly less frequent during the automated biofeedback period.</p><p><strong>Conclusions: </strong>Automated biofeedback-guided sodium control provided more precise and reproducible sodium management than a manual individualized prescription and was associated with modest improvements in interdialytic weight gain, blood pressure, and intradialytic tolerance.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of DFPP on Ferroptosis in Peripheral Blood CD14+ Monocytes of Hyperlipidemic Patients Involving the ACSL4/LPCAT3/ALOX5 Pathway.","authors":"Yun Cheng, Lan Li, Qingmei Yang, Meipeng Wu","doi":"10.1002/1744-9987.70227","DOIUrl":"https://doi.org/10.1002/1744-9987.70227","url":null,"abstract":"<p><strong>Introduction: </strong>Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid-lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non-drug treatment using double-filtration plasmapheresis (DFPP) on CD14+ monocytes and to identify alterations in plasma proteomics after DFPP in patients with hyperlipidemia.</p><p><strong>Methods: </strong>Thirty-seven hyperlipidemic patients were enrolled. Mitochondria changes, lipid peroxidation, reactive oxygen species (ROS), and mitochondrial lipid peroxidation were examined. CD14+ monocyte proteins related to ferroptosis were assayed by western blotting, and plasma proteomic changes were measured by data-independent acquisition (DIA).</p><p><strong>Results: </strong>In comparison to their levels prior to double-filtration plasmapheresis (DFPP), there was a notable reduction in total cholesterol (TC), total triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and small dense low-density lipoprotein cholesterol (sdLDL) after DFPP. DFPP may attenuate ferroptosis in peripheral blood CD14+ monocytes of patients with hyperlipidemia. Three protein candidates were identified from the DIA dataset.</p><p><strong>Conclusions: </strong>DFPP exerts lipid-lowering effects in patients with hyperlipidemia. The ACSL4/LPCAT3/ALOX5 pathway and the three proteins are likely involved in alleviating ferroptosis.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT03491956.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Multidisciplinary Management of Acute-On-Chronic Liver Failure in a Twin Pregnancy Using Artificial Liver Support: A Case Report.","authors":"Pingping Luo, Weixia Chen, Lifei Yu, Lina Wang","doi":"10.1002/1744-9987.70230","DOIUrl":"https://doi.org/10.1002/1744-9987.70230","url":null,"abstract":"<p><strong>Introduction: </strong>Acute-on-chronic liver failure (ACLF) in pregnancy is a rare, life-threatening condition with high maternal and fetal mortality.</p><p><strong>Methods: </strong>We report a twin-pregnant patient with ACLF managed by a multidisciplinary team. Interventions included comprehensive medical therapy, seven sessions of artificial liver support (plasma exchange), symptom control, nutritional and psychological care, and prophylactic measures against mother-to-child transmission.</p><p><strong>Results: </strong>The patient successfully delivered healthy twins. Postdelivery, both infants tested negative for HBsAg and HBV-DNA, confirming effective prevention of vertical transmission. Maternal condition stabilized with treatment.</p><p><strong>Conclusion: </strong>Multidisciplinary management incorporating artificial liver therapy and tailored obstetric care can achieve favorable maternal and neonatal outcomes in ACLF during twin pregnancy.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149121335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic serum profiles before and after lipoprotein apheresis in patients with peripheral artery disease with ulceration.","authors":"Kohei Ishiga, Tatsuki Uehara, Hiromichi Wakui, Kengo Azushima, Eiko Ueda, Daisuke Kanai, Mari Sotozawa, Ryu Kobayashi, Sho Kinguchi, Tomohiko Kanaoka, Tatsuya Haze, Yoshiyuki Toya, Kouichi Tamura","doi":"10.1111/1744-9987.14247","DOIUrl":"10.1111/1744-9987.14247","url":null,"abstract":"<p><strong>Introduction: </strong>The efficacy of lipoprotein apheresis (LA) in peripheral arterial disease (PAD) has been primarily attributed to its anti-atherosclerotic effects through the adsorption of lipoproteins. However, the other potential effects of LA remain unknown. We evaluated changes in serum profiles before and after LA using a comprehensive analysis to explore the underlying mechanism.</p><p><strong>Methods: </strong>Ten patients with leg ulcers were included from the LETS-PAD study, in which patients with lipoprotein-controlled PAD underwent LA. Serum samples collected at baseline and 1 month after LA were analyzed for proteomic changes.</p><p><strong>Results: </strong>Six patients exhibited ulcer epithelialization and skin perfusion pressure improvement. Proteomic analysis identified 2033 proteins. Fifty-five proteins showed significant differences. B-cell lymphoma protein-2 associated X (BAX) and C-X-C motif chemokine 10 (CXCL10) were downregulated.</p><p><strong>Conclusion: </strong>Serum BAX and CXCL10 levels significantly decreased after LA, which may be involved in the ulcer epithelialization mechanism of LA, which potentially acts through angiogenesis promotion.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"713-722"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Internal Inconsistencies Between Reported Profiles, Predictors, and Conclusions.","authors":"Emre Cankaya","doi":"10.1002/1744-9987.70191","DOIUrl":"10.1002/1744-9987.70191","url":null,"abstract":"","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"790-791"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of transcutaneous vagus nerve stimulation in hemodialysis patients: A randomized controlled trial.","authors":"Qiuling Zhang, Jun Dou, Hua Ao, Dongmei Guo, Xi Yang, Ming Li","doi":"10.1111/1744-9987.14243","DOIUrl":"10.1111/1744-9987.14243","url":null,"abstract":"<p><strong>Introduction: </strong>Transcutaneous auricular vagus nerve stimulation (tVNS) has shown potential in neurological, autoimmune, and cardiovascular disorders, but its effects on HD patients remain unclear. This study aimed to evaluate the efficacy and safety of tVNS in HD patients.</p><p><strong>Methods: </strong>We conducted a randomized controlled clinical trial on patients receiving HD ≥6 months. The tVNS group received stimulation for 1 h during the first 2 h of HD sessions, three times weekly for 8 weeks, while the control group received standard care. The primary outcomes were dialysis efficiency (Single-pool Kt/V, Sp Kt/V) and dialysis-related symptoms (Dialysis Symptom Index, DSI), assessed every 4 weeks. Secondary outcomes included pain and fatigue scores, physical performance, Hemodialysis Comfort Scale, hemoglobin levels, Mini-Mental State Examination, and anxiety and depression scores, measured at baseline and 8 weeks after intervention.</p><p><strong>Results: </strong>A total of 63 patients were enrolled in the study, with 32 patients assigned to the tVNS group and 31 patients to the control group. At 8 weeks, the tVNS group showed significant improvements in Sp Kt/V (1.31 ± 0.11 vs. 1.25 ± 0.10, p = 0.02), and DSI (12.09 ± 5.84 vs. 16.26 ± 5.27, p = 0.004), as well as reductions in pain and fatigue, and increases in physical function, comfort, and hemoglobin. However, there were no statistically significant changes observed in cognitive function, anxiety, or depression.</p><p><strong>Conclusions: </strong>tVNS could improve dialysis efficiency, symptoms, and physical function in HD patients, indicating it may have a role as a complementary therapy.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"739-748"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of patient factors on target plasma volume treated attainment rate during double filtration plasmapheresis in patients with hypertriglyceridemic acute pancreatitis.","authors":"Hui Zhang, Chenqiang Zhu, Yunlong Wu","doi":"10.1111/1744-9987.14232","DOIUrl":"10.1111/1744-9987.14232","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to investigate patient factors affecting the rate of plasma volume target attained in hypertriglyceridemic pancreatitis (HTG-AP) patients undergoing double filtration plasmapheresis (DFPP).</p><p><strong>Methods: </strong>A retrospective analysis of 82 HTG-AP-interpreted patients from January 2019 to April 2024 compared target plasma volume treated between up-to-scratch and non-scratch groups. The group comparison used independent samples t-test, Mann-Whitney U-test, and chi-square test. Binary logistic regression was used to identify independent risk factors for patients' plasma volume target failure. The ROC curve assessed these risk factors' diagnostic efficacy.</p><p><strong>Results: </strong>Of 82 patients, 52 were classified as belonging to the up-to-scratch group, while the remaining 30 were classified as belonging to the non-to-scratch group. Statistically significant differences were seen between the groups regarding admission heart rate, triglyceride, calcitonin gene, C-reactive protein, D-dimer, and fibrinogen (FIB) levels (p <0.05). The binary logistic regression analysis showed that for every 1 mmol/L increase in triglycerides (TG), the probability of experiencing substandard target plasma handling increased by 5.0% (OR = 1.05, 95%CI 1.01-1.08, p = 0.009). Furthermore, for each g/L rise in FIB, there was a 74% increase in the likelihood of encountering suboptimal target plasma handling (OR = 1.74, 95%CI 1.18-2.56, p = 0.005). The ROC curve study revealed that the AUC for TG was 0.67, for FIB was 0.77, and for the combination of both markers was 0.80; all the p values were below 0.05.</p><p><strong>Conclusion: </strong>The increased levels of TG and FIB are independent risk factors affecting the target plasma handling achievement rate in HTG-AP patients undergoing DFPP.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"690-697"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic changes in serum albumin and ferritin indicate higher risk of early-onset peritonitis in peritoneal dialysis patients.","authors":"Jinqing Li, Yao Liu, Yijun Lu, Chensheng Fu, Zhibin Ye, Zhenxing Zhang","doi":"10.1111/1744-9987.14244","DOIUrl":"10.1111/1744-9987.14244","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study is to investigate the dynamic changes in serum albumin and ferritin as potential predictors for early-onset peritoneal dialysis-related peritonitis (PDRP) in patients undergoing peritoneal dialysis (PD).</p><p><strong>Methods: </strong>This retrospective study included 215 patients with end-stage renal disease who initiated PD at Huadong Hospital. Patients were followed up to 24 months, during which episodes of PDRP were recorded. The dynamic changes in serum albumin and ferritin levels were evaluated within the first 6 months of PD initiation. Data were analyzed to assess the relationship between these biomarkers and early-onset PDRP.</p><p><strong>Results: </strong>Among the 215 patients, 33.49% developed PDRP, and 28.93% experienced early-onset PDRP. Patients with lower baseline serum albumin levels (<35 g/L) and higher baseline ferritin levels (≥400 μg/L) had an increased risk of developing early-onset PDRP. Importantly, the risk associated with low initial albumin was not significant when serum albumin levels remained stable within the first 6 months (-5% to 5% change). Similarly, although higher baseline ferritin was associated with a higher risk of early-onset PDRP, patients with fluctuating ferritin levels (more than 35% change) showed no significant increase in the risk. Kaplan-Meier analysis revealed a lower cumulative technical survival rate in patients with early-onset PDRP.</p><p><strong>Conclusion: </strong>Dynamic changes in serum albumin and ferritin levels within the first 6 months of PD can serve as significant predictors of early-onset PDRP, but stable levels of these markers mitigate their predictive value. Close monitoring of these biomarkers may help in identifying high-risk patients and improving PD outcomes.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"731-738"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced therapeutic efficacy of granulocyte/monocyte adsorption in rats with drug-induced colitis : Insights from a downsized bead column and newly formed B cells.","authors":"Yujin Nishioka, Goh Murayama, Makio Kusaoi, Daichi Takemasa, Kenta Kaneda, Taiga Kuga, Yukitomo Hagiwara, Takumi Saito, Yu Yamaji, Yoshifumi Suzuki, Tetsutaro Nagaoka, Ken Yamaji, Naoto Tamura","doi":"10.1111/1744-9987.14234","DOIUrl":"10.1111/1744-9987.14234","url":null,"abstract":"<p><strong>Introduction: </strong>Granulocyte/monocyte adsorption therapy can manage mild-to-moderate inflammatory bowel disease by removing activated granulocytes and monocytes. We evaluated granulocyte/monocyte adsorption using new columns with reduced bead size and theoretically enhanced adsorption.</p><p><strong>Methods: </strong>We assessed granulocyte/monocyte adsorption in rats with colitis by analyzing cell changes and cytokine production.</p><p><strong>Results: </strong>Granulocyte/monocyte adsorption with the new columns improved histology in rats with colitis. Contrary to expectations, the adsorption rate of granulocytes/monocytes into the blood did not show a significant improvement. However, flow cytometry showed increased B cells in peripheral blood mononuclear cells and newly formed B cells in the bone marrow, which produced more interleukin-10 than peripheral blood B cells. Newly formed B cells adoptively transferred into colitis rats accumulated at the inflammation site and tended to inhibit intestinal shortening.</p><p><strong>Conclusions: </strong>Newly formed B cells with strong interleukin-10 production may alleviate inflammation. The new columns suggest potential for controlling colitis.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"676-689"},"PeriodicalIF":1.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}